Alcon: UBS raises target price

(CercleFinance.com) - UBS has reaffirmed its 'buy' recommendation on Alcon, raising its target price from 87 CHF to 92 CHF, a new TP that represents 14% upside potential for the Swiss ophthalmology group's shares.


EPS growth in the mid-teens range is now being delivered consistently, while the outlook for catalysts over the next 12 to 18 months is rich, the broker summarises.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.